Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Shingles vaccine)
1,716 results
  • Improving herpes zoster vaccine rates: The impact of a targeted educational program. [Journal Article]
  • JAJ Am Assoc Nurse Pract 2018 Jun 04
  • OʼDonnell M, Shurpin K, Janotha B
  • CONCLUSIONS: In Phase I, NYS Primary Care NPs with practice years ranging from 1 to 24, who reported working in practice sites that ranged from 1 to 20 providers, possessed limited knowledge of the vaccine, especially, the financial aspects of the vaccination such as up-front cost (46%), cost to patients (39%), and reimbursement (29%), resulting in fewer provider recommendations. In Phase II, a paired-samples t test revealed a statistically significant difference between pretest scores (mean = 3.4, SD = 1.2) and posttest scores (mean = 4.7, SD = 1.3) on the knowledge survey, t (37) = -7.1, p < .0, demonstrating NPs' improved understanding of HZV.Nurse practitioners will increase compliance with the CDC recommendations for HZV administration.
  • Vaccine Development for Varicella-Zoster Virus. [Journal Article]
  • AEAdv Exp Med Biol 2018; 1045:123-142
  • Sadaoka T, Mori Y
  • Varicella-zoster virus (VZV) is the first and only human herpesvirus for which a licensed live attenuated vaccine, vOka, has been developed. vOka has highly safe and effective profiles; however, worl...
  • Lupus and vaccinations. [Journal Article]
  • COCurr Opin Rheumatol 2018 Jun 09
  • Mathian A, Pha M, Amoura Z
  • CONCLUSIONS: New data confirm the safety and the lower immunogenicity of pneumococcal and influenza vaccine in SLE patients. Current efforts to improve immunization coverage in SLE should focus on spreading to patients and physicians the informations on the safety, efficacy and usefulness of vaccines in this population.
  • Herpes zoster subunit vaccine for the prevention of herpes zoster. [Review]
  • AJAm J Health Syst Pharm 2018 Jun 15; 75(12):861-869
  • Symoniak MR, Farrokh P, … Slish JC
  • CONCLUSIONS: HZ/su vaccine (Shingrix, GlaxoSmithKline) is a recently Food and Drug Administration (FDA)-approved vaccine indicated for the prevention of HZ in adults 50 years of age and older. Based on several Phase III trials, the Advisory Committee on Immunization Practices has preferentially recommended HZ/su vaccine over a live attenuated vaccine previously approved by FDA. Reported overall HZ/su vaccine efficacy in preventing HZ in Phase III trials ranged from 89.8% to 97.2%. Compared with placebo use, HZ/su vaccine in those trials was associated with higher rates of transient local and systemic adverse events (AEs) but similar rates of serious vaccine-related AEs. Other clinical trials of HZ/su vaccine have yielded favorable results in various populations, including adults with a history of HZ, older adults who previously received live attenuated zoster vaccine, adults with human immunodeficiency virus infection, and stem cell transplant recipients.HZ/su vaccine is a recently approved, preferred option to reduce the risks of HZ and PHN in adults 50 years of age or older. Pain at the injection site is the most common AE associated with use of the vaccine.
New Search Next